Opinion|Videos|January 31, 2025
Navigating the Evolving Treatment Landscape in R/R FL: When to Consider BTK and EZH2 Inhibitors
Panelists discuss how they collaborate with community sites for chimeric antigen receptor (CAR) T and bispecifics administration, accessibility, and monitoring, and explore the factors influencing the use of tazemetostat or zanubrutinib + obinutuzumab, including patient selection, accessibility, and sequencing in relation to CAR T or bispecific therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you partner or collaborate with community sites regarding CAR T and bispecifics administration, accessibility, and monitoring?
- Which patients do you consider tazemetostat or zanubrutinib + obinutuzumab for, and how does accessibility of these agents factor? How are you sequencing these agents in relationship to CAR T or the bispecifics?
Advertisement
Related to this article
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
Japan approved subcutaneous pembrolizumab and berahyaluronidase alfa across all indications for which intravenous pembrolizumab is approved in the country.
New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5